Cancer Associated Thrombosis Circulatory System
Conditions
Interventions
Consenting patients will be randomised to one of two trial arms:
Arm A - Continue LMWH at treatment dose according to body weight for further six months.
Arm B - Discon
10-15)
2. Trial participants in the intervention arm (10-15)
3. Trial participants in the control arm (10-15)
4. Carers of trial participants (10-15)
Sponsors
Cardiff University (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Receiving low-molecular-weight heparin (LMWH) for treatment of Cancer Associated Thrombosis (CAT) for five months 2. Locally advanced or metastatic cancer 3. Able to self-administer LMWH, or have LMWH administered by a carer 4. Able to give informed consent 5. Age =18 years
Exclusion criteria
Exclusion criteria: 1. Receiving drug other than LMWH for CAT 2. Contraindication to anticoagulation 2.1. Known allergies to LMWHs, heparin, sulfites or benzyl alcohol 2.2. Active major bleeding 2.3. History of heparin-induced thrombocytopenia 3. Confirmed recurrent VTE whilst receiving anticoagulation 4. Female patients who are pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Number of eligible patients over 12 months 2. Number of recruited patients over 12 months (target recruitment rate of 30% of eligible patients) 3. Proportion of participants with recurrent VTEs during follow-up | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Completion of trial protocol 2. Quality of life 3. Symptom assessment 4. Attitudes of clinicians and patients | — |
Countries
United Kingdom
Outcome results
None listed